Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a large decline in short interest in May. As of May 29th, there was short interest totaling 61,636 shares, a decline of 51.3% from the May 14th total of 126,538 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 629,575 shares, the days-to-cover ratio is presently 0.1 days.

Azitra Stock Down 6.5%

AZTR stock traded down $0.01 during mid-day trading on Monday, hitting $0.20. The company had a trading volume of 716,688 shares, compared to its average volume of 430,090. Azitra has a 12-month low of $0.10 and a 12-month high of $2.40. The company has a 50-day moving average price of $0.22 and a 200 day moving average price of $0.24.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.24). Analysts predict that Azitra will post -0.25 EPS for the current fiscal year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.